OnKure Therapeutics, Inc. reported Q4 and full year 2025 financial results, including $59.1 million in cash and cash equivalents as of December 31, 2025, R&D expenses of $10.7 million, G&A expenses of $3.4 million, and net loss of $13.5 million or $0.99 per share. The company highlighted progress in the PIKture-01 trial of OKI-219 and expects to announce updated data and a next-generation PI3Kα pan-mutant inhibitor in March 2026.
Key takeaways
Cash and cash equivalents $59,050 thousand as of December 31, 2025
Q4 2025 R&D expenses $10,720 thousand vs $14,361 thousand in Q4 2024
Q4 2025 G&A expenses $3,405 thousand vs $4,338 thousand in Q4 2024
Q4 2025 net loss $13,503 thousand or $(0.99) per share vs $17,442 thousand or $(1.37) per share in Q4 2024
71 patients dosed in PIKture-01 Parts A and B (monotherapy and fulvestrant combination)
17 patients dosed in PIKture-01 Part E (triplet with fulvestrant and ribociclib)
Updated PIKture-01 data and next-generation PI3Kα pan-mutant inhibitor announcement expected March 2026